Respiratory syncytial virus immunoprophylaxis in high-risk infants and development of childhood asthma.

نویسندگان

  • Kecia N Carroll
  • Tebeb Gebretsadik
  • Gabriel J Escobar
  • Pingsheng Wu
  • Sherian Xu Li
  • Eileen M Walsh
  • Ed Mitchel
  • Chantel D Sloan
  • William D Dupont
  • Tina V Hartert
چکیده

BACKGROUND Respiratory syncytial virus (RSV) lower respiratory tract infection is implicated in asthma development. RSV immunoprophylaxis during infancy is efficacious in preventing RSV-related hospitalizations and has been associated with decreased wheezing in the first years of life. OBJECTIVE We investigated whether greater adherence to immunoprophylaxis in infants at high risk for severe RSV would be associated with decreased childhood asthma. METHODS We conducted a retrospective cohort investigation including children born from 1996-2003 who were enrolled in Kaiser Permanente Northern California or Tennessee Medicaid and eligible to receive RSV immunoprophylaxis. Asthma was defined at 4.5 to 6 years of age by using asthma-specific health care visits and medication fills. We classified children into immunoprophylaxis eligibility groups and calculated adherence (percentage receipt of recommended doses). We used a set of statistical strategies (multivariable logistic regression and propensity score [PS]-adjusted and PS-matched analyses) to overcome confounding by medical complexity because infants with higher adherence (≥70%) have higher prevalence of chronic lung disease, lower birth weight, and longer nursery stays. RESULTS By using multivariable logistic regression and PS-adjusted models in the combined group, higher adherence to RSV immunoprophylaxis was not associated with decreased asthma. However, in PS-matched analysis, treated children with 70% or greater adherence had decreased odds of asthma compared with those with 20% or less adherence (odds ratio, 0.62; 95% CI, 0.50-0.78). CONCLUSIONS This investigation of RSV immunoprophylaxis in high-risk children primarily found nonsignificant associations on prevention of asthma in specific preterm groups. Our findings highlight the need for larger studies and prospective cohorts and provide estimates of potential preventive effect sizes in high-risk children.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract infections in infants and small chil-

Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract infections in infants and small children worldwide. There is no cure for RSV disease, but immunoprophylaxis using humanized monoclonal antibody has proven to be safe and efficacious in preventing disease. Extensive research supports the hypothesis that RSV bronchiolitis in infancy results in increased risk for develo...

متن کامل

Introduction. RSV and RAD: possibilities for prevention? The link between respiratory syncytial virus and reactive airway disease

Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract infections in infants and small children worldwide. There is no cure for RSV disease, but immunoprophylaxis using humanized monoclonal antibody has proven to be safe and efficacious in preventing disease. Extensive research supports the hypothesis that RSV bronchiolitis in infancy results in increased risk for develo...

متن کامل

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.

Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous (RSV-IGIV) are licensed by the Food and Drug Administration for use in preventing severe lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk infants, children younger than 24 months with chronic lung disease (formerly called bronchopulmonary dysplasia), and certain preterm infants. Th...

متن کامل

The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area.

AIMS To describe the clinical and health economic impact of respiratory syncytial virus (RSV) disease in children under 2 years of age. METHODS Hospitalised children less than 2 years of age with a respiratory illness were studied over three consecutive RSV seasons (1996-99). RESULTS The rates (per 1000 infants under 1 year of age) of hospitalisations from bronchiolitis and RSV illness were...

متن کامل

Authors' response re: Clarifying costs and benefits of respiratory syncytial virus immunoprophylaxis.

The stated hospitalization cost of $8530 (2009$) is not representative of respiratory syncytial virus (RSV) hospitalizations among palivizumab-eligible infants; it is the average cost of bronchiolitis hospitalizations among US children ,2 years.2 Using the same source, the Kids’ Inpatient Database, the average RSV hospitalization (International Classification of Diseases, Ninth Revision, Clinic...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • The Journal of allergy and clinical immunology

دوره 139 1  شماره 

صفحات  -

تاریخ انتشار 2017